Tactile Systems Technology, Inc. (TCMD)

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Tactile Systems Technology (TCMD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TCMD broke through the 20-day moving average, which suggests a short-term bullish trend.

Tactile Systems Technology (TCMD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TCMD broke out above the 50-day moving average, suggesting a short-term bullish trend.

Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q2 2025 Earnings Conference Call August 4, 2025 5:00 PM ET Company Participants Elaine M. Birkemeyer - Chief Financial Officer Sheri Louise Dodd - CEO, President & Director Conference Call Participants Anderson Schock - B.

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.2 per share a year ago.

Tactile Systems (TCMD) Q2 Revenue Up 8%

MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 7.8% year-over-year to $78.9 million Gross margin of 75% versus 74% in Q2 2024 Net income of $3.2 million versus $4.3 million in Q2 2024 Adjusted EBITDA of $7.7 million versus $9.1 million in Q2 2024 Announced the presentation of new data demonstrating significant benefits associated with use of Flexitouch Plus in treating patients with head and neck cancer-related lymphedema Repurchased $16.5 million of stock to complete the Company's share repurchase program “We delivered strong financial performance in the second quarter, marked by total revenue growth of nearly 8% year-over-year and ahead of our previously stated expectations,” said Sheri Dodd, Chief Executive Officer of Tactile Medical.

MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2025 financial results will be released after the market closes on Monday, August 4, 2025.

After lagging behind large-cap peers for the past two years, small-cap stocks may finally be poised for a breakout in the second half of 2025. With interest rate cuts potentially on the horizon, improving macroeconomic conditions, and attractive relative valuations, institutional investors are beginning to rotate into this overlooked segment of the market.

Abstract Presented at ASCO 2025 Annual Meeting Features Two-Month Data from the Largest Randomized Trial Ever Conducted Among Head and Neck Cancer Survivors Abstract Presented at ASCO 2025 Annual Meeting Features Two-Month Data from the Largest Randomized Trial Ever Conducted Among Head and Neck Cancer Survivors

MINNEAPOLIS, May 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will be participating in two upcoming investor conferences. Tactile Medical is scheduled to present at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 3:20 p.m. CST and at the Jefferies Global Healthcare Conference in New York on Wednesday, June 4, 2025, at 2:35 p.m. EST.

Tactile Systems Technology, Inc. TCMD traded lower on Tuesday after the company's Q1 earnings missed Wall Street expectations on Monday.

Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd - Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Margaret Kaczor Andrew - William Blair Ryan Zimmerman - BTIG Anderson Schock - B. Riley Securities Operator Welcome, ladies and gentlemen, to the First Quarter 2025 Earnings Conference Call for Tactile Medical.

Tactile Systems Technology (TCMD) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.05 per share a year ago.

MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025.